https://www.selleckchem.com/pr....oducts/pf-04957325.h
BACKGROUND NSCLC is the major type of lung cancer and the survival rates of NSCLC patients remain low. AZD9291 is a third-generation EGFR-TKI and approved to treat NSCLC patients harboring EGFR T790M mutation and common targetable activating EGFR mutations, but it has a limited effect for wtEGFR NSCLC. PURPOSE The current study investigated whether shikonin could enhance the antitumor effect of AZD9291 in wtEGFR NSCLC cells. METHODS SRB and colony formation assay were used to detect the proliferation of NSCLC cells, propidium iodide
Like
Comment
Share
